147 related articles for article (PubMed ID: 24316906)
1. SATB2 is a novel marker of osteoblastic differentiation and colorectal adenocarcinoma.
Ordóñez NG
Adv Anat Pathol; 2014 Jan; 21(1):63-7. PubMed ID: 24316906
[TBL] [Abstract][Full Text] [Related]
2. SATB2 as an Immunohistochemical Marker for Colorectal Adenocarcinoma: A Concise Review of Benefits and Pitfalls.
Berg KB; Schaeffer DF
Arch Pathol Lab Med; 2017 Oct; 141(10):1428-1433. PubMed ID: 28968158
[TBL] [Abstract][Full Text] [Related]
3. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
4. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas.
Magnusson K; de Wit M; Brennan DJ; Johnson LB; McGee SF; Lundberg E; Naicker K; Klinger R; Kampf C; Asplund A; Wester K; Gry M; Bjartell A; Gallagher WM; Rexhepaj E; Kilpinen S; Kallioniemi OP; Belt E; Goos J; Meijer G; Birgisson H; Glimelius B; Borrebaeck CA; Navani S; Uhlén M; O'Connor DP; Jirström K; Pontén F
Am J Surg Pathol; 2011 Jul; 35(7):937-48. PubMed ID: 21677534
[TBL] [Abstract][Full Text] [Related]
5. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA
Hum Pathol; 2017 Sep; 67():152-159. PubMed ID: 28711650
[TBL] [Abstract][Full Text] [Related]
6. SATB2 Expression Is Sensitive but Not Specific for Osteosarcomatous Components of Gynecologic Tract Carcinosarcomas: A Clinicopathologic Study of 60 Cases.
Sangoi AR; Kshirsagar M; Horvai AE; Roma AA
Int J Gynecol Pathol; 2017 Mar; 36(2):140-145. PubMed ID: 27294605
[TBL] [Abstract][Full Text] [Related]
7. Special AT-rich sequence-binding protein 2 (SATB2) expression is sensitive but may not be specific for osteosarcoma as compared with other high-grade primary bone sarcomas.
Davis JL; Horvai AE
Histopathology; 2016 Jul; 69(1):84-90. PubMed ID: 26644288
[TBL] [Abstract][Full Text] [Related]
8. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours.
Conner JR; Hornick JL
Histopathology; 2013 Jul; 63(1):36-49. PubMed ID: 23701429
[TBL] [Abstract][Full Text] [Related]
9. SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours.
Hoskoppal D; Epstein JI; Gown AM; Arnold Egloff SA; Gordetsky JB; Shi CJ; Giannico GA
Histopathology; 2020 Mar; 76(4):550-559. PubMed ID: 31595536
[TBL] [Abstract][Full Text] [Related]
10. The role of SATB2 as a diagnostic marker for tumors of colorectal origin: Results of a pathology-based clinical prospective study.
Dragomir A; de Wit M; Johansson C; Uhlen M; Pontén F
Am J Clin Pathol; 2014 May; 141(5):630-8. PubMed ID: 24713733
[TBL] [Abstract][Full Text] [Related]
11. Young investigator challenge: Cadherin-17 and SATB2 in cytology specimens: Do these new immunostains help in differentiating metastatic colorectal adenocarcinoma from adenocarcinomas of other origins?
Brandler TC; Jelloul FZ; Soto D; Das K; Rosen L; Bhuiya TA
Cancer Cytopathol; 2015 Dec; 123(12):706-13. PubMed ID: 26671737
[TBL] [Abstract][Full Text] [Related]
12. Role of conventional immunomarkers, HNF4-α and SATB2, in the differential diagnosis of pulmonary and colorectal adenocarcinomas.
Kriegsmann M; Harms A; Longuespée R; Muley T; Winter H; Kriegsmann K; Kazdal D; Goeppert B; Pathil A; Warth A
Histopathology; 2018 May; 72(6):997-1006. PubMed ID: 29243296
[TBL] [Abstract][Full Text] [Related]
13. Loss of SATB2 Expression in Colorectal Carcinoma Is Associated With DNA Mismatch Repair Protein Deficiency and BRAF Mutation.
Ma C; Olevian DC; Lowenthal BM; Jayachandran P; Kozak MM; Chang DT; Pai RK
Am J Surg Pathol; 2018 Oct; 42(10):1409-1417. PubMed ID: 30001238
[TBL] [Abstract][Full Text] [Related]
14. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.
Machado I; Navarro S; Picci P; Llombart-Bosch A
Pathol Res Pract; 2016 Sep; 212(9):811-6. PubMed ID: 27465835
[TBL] [Abstract][Full Text] [Related]
15. Contribution of SATB2 to the stronger osteogenic potential of bone marrow stromal cells from craniofacial bones.
Zhang P; Men J; Fu Y; Shan T; Ye J; Wu Y; Tao Z; Liu L; Jiang H
Cell Tissue Res; 2012 Dec; 350(3):425-37. PubMed ID: 22955562
[TBL] [Abstract][Full Text] [Related]
16. miR-383 negatively regulates osteoblastic differentiation of bone marrow mesenchymal stem cells in rats by targeting Satb2.
Tang J; Zhang Z; Jin X; Shi H
Bone; 2018 Sep; 114():137-143. PubMed ID: 29909059
[TBL] [Abstract][Full Text] [Related]
17. Colitis-associated colorectal adenocarcinomas are frequently associated with non-intestinal mucin profiles and loss of SATB2 expression.
Iwaya M; Ota H; Tateishi Y; Nakajima T; Riddell R; Conner JR
Mod Pathol; 2019 Jun; 32(6):884-892. PubMed ID: 30710095
[TBL] [Abstract][Full Text] [Related]
18. [Significance of SATB2 in the pathologic diagnosis of osteosarcoma].
Li M; Cai YP; Lu KY; Chen Y; Zhu X; Yin Y; Tang J
Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):631-5. PubMed ID: 27646893
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological, immunohistochemical, and mutational analyses of pulmonary enteric adenocarcinoma: usefulness of SATB2 and β-catenin immunostaining for differentiation from metastatic colorectal carcinoma.
Matsushima J; Yazawa T; Suzuki M; Takahashi Y; Ota S; Nakajima T; Yoshino I; Yokose T; Inoue T; Kawahara K; Nakatani Y
Hum Pathol; 2017 Jun; 64():179-185. PubMed ID: 28438615
[TBL] [Abstract][Full Text] [Related]
20. SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary.
Dabir PD; Svanholm H; Christiansen JJ
APMIS; 2018 Jun; 126(6):494-500. PubMed ID: 29924451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]